129 related articles for article (PubMed ID: 22215016)
21. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
Candotti F
J Clin Immunol; 2018 Jan; 38(1):13-27. PubMed ID: 29086100
[TBL] [Abstract][Full Text] [Related]
22. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a core region in the A2UCOE that confers effective anti-silencing activity.
Zhang F; Santilli G; Thrasher AJ
Sci Rep; 2017 Aug; 7(1):10213. PubMed ID: 28860464
[TBL] [Abstract][Full Text] [Related]
24. Eleventh International Foamy Virus Conference-Meeting Report.
Buseyne F; Gessain A; Soares MA; Santos AF; Materniak-Kornas M; Lesage P; Zamborlini A; Löchelt M; Qiao W; Lindemann D; Wöhrl BM; Stoye JP; Taylor IA; Khan AS
Viruses; 2016 Nov; 8(11):. PubMed ID: 27886074
[TBL] [Abstract][Full Text] [Related]
25. Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency.
Nasimuzzaman M; Lynn D; Ernst R; Beuerlein M; Smith RH; Shrestha A; Cross S; Link K; Lutzko C; Nordling D; Russell DW; Larochelle A; Malik P; Van der Loo JC
Mol Ther Methods Clin Dev; 2016; 3():16004. PubMed ID: 27722179
[TBL] [Abstract][Full Text] [Related]
26. The long terminal repeat negative control region is a critical element for insertional oncogenesis after gene transfer into hematopoietic progenitors with Moloney murine leukemia viral vectors.
Ikawa Y; Uchiyama T; Jagadeesh GJ; Candotti F
Gene Ther; 2016 Nov; 23(11):815-818. PubMed ID: 27487944
[TBL] [Abstract][Full Text] [Related]
27. High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells.
Nasimuzzaman M; Kim YS; Wang YD; Persons DA
Mol Ther Methods Clin Dev; 2014; 1():14020. PubMed ID: 26015964
[TBL] [Abstract][Full Text] [Related]
28. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells.
Müller-Kuller U; Ackermann M; Kolodziej S; Brendel C; Fritsch J; Lachmann N; Kunkel H; Lausen J; Schambach A; Moritz T; Grez M
Nucleic Acids Res; 2015 Feb; 43(3):1577-92. PubMed ID: 25605798
[TBL] [Abstract][Full Text] [Related]
29. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.
Candotti F
Int J Hematol; 2014 Apr; 99(4):383-92. PubMed ID: 24488786
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
[TBL] [Abstract][Full Text] [Related]
32. Advances in foamy virus vector technology and disease correction could speed the path to clinical application.
Verhoeyen E
Mol Ther; 2012 Jun; 20(6):1105-7. PubMed ID: 22652999
[No Abstract] [Full Text] [Related]
33. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
34. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
[TBL] [Abstract][Full Text] [Related]
35. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
36. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
37. Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.
Uchiyama T; Adriani M; Jagadeesh GJ; Paine A; Candotti F
Mol Ther; 2012 Jun; 20(6):1270-9. PubMed ID: 22215016
[TBL] [Abstract][Full Text] [Related]
38. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
